Johnson & Johnson’s Janssen unit has announced phase 3 results showing that its ponesimod tablet outperformed Sanofi’s Aubagio pill in adults with relapsing multiple sclerosis.
Novartis’ biosimilars and generics arm Sandoz has struck a deal with Polpharma Biologics to market a proposed biosimilar of Biogen’s multiple sclerosis drug Tysabri (natalizumab).<
Novartis has announced data supporting a cancer drug it acquired from GlaxoSmithKline and Genmab in a new use in multiple sclerosis, with plans for regulatory filings later this year.
With Merck KGaA’s multiple sclerosis drug evobrutinib entering phase 3 trials, we spoke to the company’s Fernando Dangond and MS expert Dr Xavier Montalban to get their views on the biggest